Centro di Riferimento Oncologico della Basilicata, Potenza
Dosimetry of docetaxel plus estramustine performed for prostate cancer
Published in FDA Law Weekly, November 24th, 2005
According to a study from Italy, "The aim of this phase I study was to find the maximum tolerated dose of weekly docetaxel in association with estramustine in hormone-refractory prostate cancer. Eleven patients with hormone-refractory prostate cancer were treated with escalating weekly doses of docetaxel (level I, 3 patients, 30 mg/m2; level II, 3 patients, 35 mg/m2, level III, 3 patients, 40 mg/m2; level IV, 2 patients, 45 mg/m2) associated with fixed dosage of estramuscine (840...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2005-11-24)
More Articles from FDA Law Weekly
- Aethlon Medical, Inc.
CEO discusses Project BioShield legislation and treatment strategies for biological weapons - Alba Therapeutics Corp.
First human trial for AT-1001 completed; U.S. FDA grants fast-track designation - Allergy and Immunology Associates of Ann Arbor
Long-term budesonide inhalation well tolerated in children with asthma - AlphaVax
Vaccine maker reports $3.3M grant to develop smallpox vaccine - Alza Corp.
Letter issued from U.S. FDA on Dapoxetine application - Amarillo Biosciences, Inc.
Low dose oral interferon licensed to Global Kinetics for sale in three Asian countries - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
